Ubs Asset Management Americas Inc Recursion Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 6,408,524 shares of RXRX stock, worth $26.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,408,524
Previous 2,259,178
183.67%
Holding current value
$26.8 Million
Previous $15.3 Million
121.98%
% of portfolio
0.01%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding RXRX
# of Institutions
365Shares Held
286MCall Options Held
3.28MPut Options Held
3.16M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl34.8MShares$146 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.3MShares$135 Million0.0% of portfolio
-
Baillie Gifford & CO24.4MShares$102 Million0.12% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$72.4 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$61.3 Million0.27% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $754M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...